Compare AMC & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMC | TMDX |
|---|---|---|
| Founded | 1920 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2007 | 2019 |
| Metric | AMC | TMDX |
|---|---|---|
| Price | $2.90 | $70.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $3.20 | ★ $98.73 |
| AVG Volume (30 Days) | ★ 21.2M | 716.7K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | ★ $4,848,900,000.00 | $605,494,000.00 |
| Revenue This Year | $15.83 | $22.57 |
| Revenue Next Year | $3.49 | $17.85 |
| P/E Ratio | ★ N/A | $118.03 |
| Revenue Growth | 4.57 | ★ 37.13 |
| 52 Week Low | $0.93 | $60.11 |
| 52 Week High | $3.40 | $156.00 |
| Indicator | AMC | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 35.14 |
| Support Level | $2.34 | $66.64 |
| Resistance Level | $2.93 | $71.14 |
| Average True Range (ATR) | 0.17 | 3.93 |
| MACD | -0.02 | -0.60 |
| Stochastic Oscillator | 26.67 | 21.18 |
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.